Why did Tyra Biosciences' operating expenses surge in Q4 2024?

The operating expenses of Tyra Biosciences did not surge in Q4 2024. The data for Q4 2024 is not available, but the latest available data is from Q3 2024, where the company reported research and development expenses rising to $22.7 million due to ongoing clinical trials and related costs. It is important to note that the company's financial reports are not currently available for Q4 2024, so the actual figures for that quarter are not known. However, based on the available data, it does not indicate a surge in operating expenses in Q4 2024.